Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

NCT05885464 is registered in ClinicalTrials.gov with Beam Therapeutics Inc. as lead sponsor.

NCT NCT05885464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05885464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Lead sponsor
Beam Therapeutics Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 25, 2023
Completion date
December 31, 2026
Enrollment
5 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic leukemia, lymphoblastic lymphoma, t-cell lymphoblastic leukemia/lymphoma